Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal JURNAL FARMASIMED (JFM) SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL
Putri Nurhidayah, Eka
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Evaluation of Fondaparinux Use on Kidney Function in Hospitalized COVID-19 Patients with Decreased eGFR Putri Nurhidayah, Eka; Didik Hasmono; Ruddy Hartono
Jurnal FARMASIMED (JFM) Vol 7 No 2 (2025): Jurnal Farmasimed (JFM)
Publisher : Fakultas Farmasi Institut Kesehatan Medistra Lubuk Pakam

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35451/jfm.v7i2.2731

Abstract

Background: The COVID-19 pandemic has resulted in increased hospitalization rates among patients with multisystem complications, including coagulation disorders and decreased renal function. Fondaparinux, a synthetic anticoagulant with a lower risk of thrombocytopenia, is often used as an alternative to heparin. However, its use in patients with reduced glomerular filtration rate (eGFR) remains debatable, as its elimination is dependent on renal function. Objective: This study aims to evaluate the impact of fondaparinux on renal function, specifically examining changes in eGFR and serum creatinine levels in COVID-19 patients with impaired renal function during treatment at Bhayangkara South Surabaya Hospital. Methods: This research employed a retrospective observational quantitative approach, involving COVID-19 patients who received fondaparinux at the inpatient facility of Bhayangkara Hospital from June 2020 to October 2021. Data were collected from the medical records of patients during their hospitalization, including fondaparinux dosage and eGFR and serum creatinine values, as well as other relevant clinical parameters. Statistical analysis using the Wilcoxon test was conducted to assess significant differences in serum creatinine and eGFR values following fondaparinux administration. Results: Of the 535 patients analyzed, 56 medical records met the inclusion criteria. The results of the Wilcoxon test analysis showed that there was a significant increase in eGFR (p-value 0.012, CI 95%; p-value 0.043, CI 95%; p-value 0.000, CI 95%), a substantial decrease in SCr (p-value 0.035, CI 95%; p-value 0.043, CI 95%; p-value 0.000, CI 95%) based on each degree of COVID-19 severity. Conclusion: The use of fondaparinux may improve kidney function, as indicated by significant decrease in serum creatinine and an increase in eGFR. Furthermore, no bleeding incidents were observed during the use of fondaparinux.
EVALUATION OF DRUG INTERACTION RISK AND PATTERNS IN HYPERTENSIVE PATIENTS WITH COMORBIDITIES IN A HOSPITAL SETTING Putri Nurhidayah, Eka
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.9038

Abstract

hhhhHypertension is a chronic condition with a high prevalence and is frequently accompanied by comorbidities that require polypharmacy, thereby increasing the risk of drug–drug interactions (DDIs). This study aimed to evaluate the risk and patterns of DDIs among hypertensive inpatients with comorbidities using a retrospective observational design based on medical record data from 2023–2024. Descriptive analysis was performed on patient characteristics, antihypertensive regimens, and potential DDIs using scientific literature and standardized interaction-checking tools (Medscape, DrugBank, Drugs.com). Validation was conducted independently by a clinical pharmacy practitioner and a clinical pharmacy researcher. Of the 182 medical records reviewed, 65 met the inclusion criteria. Most patients were aged ≥60 years (56.9%) and female (55.4%). A total of 56.9% of patients experienced potential DDIs. Moderate-risk interactions most frequently involved pharmacodynamic mechanisms, particularly aspirin–furosemide, nifedipine–alprazolam, valsartan–insulin glargine, and candesartan–meloxicam. Major interactions were identified in combinations such as valsartan–spironolactone and ramipril–spironolactone, which may increase the risk of hyperkalemia, as well as diltiazem–bisoprolol, which has an additive effect on SA/AV nodal conduction.These findings highlight that hypertensive patients with comorbidities are at high risk for DDIs. Regular clinical monitoring and systematic medication review by clinical pharmacists are essential to enhance therapeutic safety and effectiveness in hospital settings.
Co-Authors Didik Hasmono Ruddy Hartono